1-3 of 3
Ernest Hawk
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genetic variation in the cytochrome P450 2C9 enzyme and dose of Celecoxib in the prevention of colorectal adenoma

Free
Andrew Chan, Ann Zauber, Meier Hsu, Aurora Breazna, David Hunter, Rebecca Rosenstein, Craig Eagle, Ernest Hawk, Monica Bertagnolli
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): B32.
Published: 15 August 2014
View articletitled, Genetic variation in the cytochrome P450 2C9 enzyme and dose of Celecoxib in the prevention of colorectal adenoma
Journal Articles

A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People with Dysplasia of the Bronchial Epithelium

Free
Stephen Lam, Jean C. leRiche, Annette McWilliams, Calum MacAulay, Yulia Dyachkova, Eva Szabo, John Mayo, Robert Schellenberg, Andy Coldman, Ernest Hawk, Adi Gazdar
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (19): 6502–6511.
https://doi.org/10.1158/1078-0432.CCR-04-0686
Published: 08 October 2004
View articletitled, A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People with Dysplasia of the Bronchial Epithelium
Open the PDF for A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People with Dysplasia of the Bronchial Epithelium in another window
Journal Articles

Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis

Free
Rosalind van Stolk, Gary Stoner, William L. Hayton, Kenneth Chan, Barry DeYoung, Laura Kresty, Brian H. Kemmenoe, Paul Elson, Lisa Rybicki, James Church, Kim Provencher, Denise McLain, Ernest Hawk, Ben Fryer, Gary Kelloff, Ram Ganapathi, G. Thomas Budd
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (1): 78–89.
Published: 01 January 2000
View articletitled, Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis
Open the PDF for Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis in another window